Eli Lilly shares surged 13.2% post-earnings as the company delivered standout top-line growth, marked by a 56% YoY revenue increase and strong outperformance from key products. The initial U.S. launch of oral GLP-1 Foundayo further lifted sentiment, signaling investor optimism on future growth drivers.

• Revenue grew 56% versus Q1 2025, propelled by blockbuster performance from products like Seman and Monjaro.
• Non-GAAP earnings per share reached $8.55, up from $3.34 in the prior year quarter.
• Non-GAAP performance margin expanded by approximately 7 percentage points year-on-year to 50%, despite a 1 percentage point decline in gross margin.
• The U.S. approval and initial rollout of Foundayo (oral GLP-1 for obesity) marked a significant pipeline milestone, with global regulatory filings underway.
• The company maintained its pipeline momentum, announcing multiple positive Phase III results and closing several business development acquisitions, while increasing R&D and SG&A investments to support future growth.